[
  {
    "ts": null,
    "headline": "Jefferies Upgrades Bristol-Myers Squibb (BMY)",
    "summary": "Jefferies Upgrades Bristol-Myers Squibb (BMY)",
    "url": "https://finnhub.io/api/news?id=0ebdae4729f6999f922fc81ea1d7a2c0fecbf51c5a3af322ebfcd05c727a99e0",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734378054,
      "headline": "Jefferies Upgrades Bristol-Myers Squibb (BMY)",
      "id": 132015469,
      "image": "",
      "related": "BMY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0ebdae4729f6999f922fc81ea1d7a2c0fecbf51c5a3af322ebfcd05c727a99e0"
    }
  },
  {
    "ts": null,
    "headline": "Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases",
    "summary": "RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.",
    "url": "https://finnhub.io/api/news?id=e960c6b5df2e8fb66d07be9fb1bfe08e887b496725a3def855cc73a2f39af7e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734374400,
      "headline": "Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases",
      "id": 132016434,
      "image": "https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.",
      "url": "https://finnhub.io/api/news?id=e960c6b5df2e8fb66d07be9fb1bfe08e887b496725a3def855cc73a2f39af7e8"
    }
  },
  {
    "ts": null,
    "headline": "Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy",
    "summary": "Investing.com -- Jefferies upgraded Bristol-Myers Squibb Company (NYSE:BMY) to \"buy\" from \"hold\" and raised its price target by $7 to $70, amid an improved confidence in the company’s product pipeline, disciplined spending, and greater clarity on regulatory risks.",
    "url": "https://finnhub.io/api/news?id=beb660f7be62c79d62ca653740fad3d84d1a09aeadff115d86cad65d997cccf4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734371283,
      "headline": "Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy",
      "id": 132014598,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- Jefferies upgraded Bristol-Myers Squibb Company (NYSE:BMY) to \"buy\" from \"hold\" and raised its price target by $7 to $70, amid an improved confidence in the company’s product pipeline, disciplined spending, and greater clarity on regulatory risks.",
      "url": "https://finnhub.io/api/news?id=beb660f7be62c79d62ca653740fad3d84d1a09aeadff115d86cad65d997cccf4"
    }
  },
  {
    "ts": null,
    "headline": "BMY vs. VRTX: Which Stock Is the Better Value Option?",
    "summary": "BMY vs. VRTX: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=601c81d4ab784ce299905448dd9d0933fa1d5eddf74fb6cbd60422320ac09047",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734367213,
      "headline": "BMY vs. VRTX: Which Stock Is the Better Value Option?",
      "id": 132014599,
      "image": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY vs. VRTX: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=601c81d4ab784ce299905448dd9d0933fa1d5eddf74fb6cbd60422320ac09047"
    }
  }
]